
Acurx Pharmaceuticals fell 77.2% from $4.34 to $0.99, behind the S&P 500's +11.0%. Its worst day was Mar 13 (−22.6%), and its low came Nov 16 at $0.94.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Acurx Pharmaceuticals shares rose 38.0%, while the S&P 500 fell 0.3%.
+38.0% · S&P 500 −0.3%
EPS of $-0.73 beat the $-1.00 estimate on $0.00 revenue.
−22.6%, the year's worst day · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
EPS of $-0.62 beat the $-0.63 estimate on $0.00 revenue.
−6.0% · S&P 500 −0.2%
EPS of $-0.53 missed the $-0.43 estimate on $0.00 revenue.
−5.7% · S&P 500 −0.2%
EPS of $-0.49 missed the $-0.43 estimate on $0.00 revenue.
−4.4% · S&P 500 −0.4%
Where it ended: a close of $0.99 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 12, 2027 (EPS est. $-0.45).
Nothing in the past 12 months.
All ACXP dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ACXP and SPY from Benzinga historical bars. Not investment advice.